PsychoGenics is a rapidly growing innovative preclinical CNS service provider with expertise in the fields of psychopharmacology, behavioral testing, molecular biology and informatics. The firm has an established service business, with more than 160 repeat pharmaceutical, biotechnology and not-for-profit, domestic and international clients. PsychoGenics offers over 80 different behavioral tests to phenotype rodent disease models and test drug candidates in the areas of psychiatric and neurodegenerative disorders, pain and inflammation, and spinal cord and traumatic brain injury. The company is able to compliment their behavioral expertise with other capabilities, including electrophysiology, molecular biology, neurogenesis, state of the art microdialysis and a variety of in-licensed transgenic mouse models that support research in areas such as Alzheimers disease, Huntingtons disease, Parkinsons disease, Autism spectrum disorders, psychosis/schizophrenia, Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders.
